List view / Grid view
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…
Scientists have developed a monoclonal antibody drug that could help to prevent infection from Acinetobacter baumannii.
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings.…
Introducing Kristina Torfgard! Holding a PhD in Clinical Pharmacology, she has over 30 years’ experience in drug development and is currently CEO of IRLAB Therapeutics.
NpG-D-PSMA has shown great potential for targeted alpha therapy to combat prostate cancer.
The findings could aid the design of more stable drugs and improve the understanding of diseases linked to peptide aggregation.
The nucleic acid drug, iSN04, could have applications for pathological angiogenesis involved in atherosclerosis, cancer, and retinopathy.
Nadine Sprangers is Vice President, Head of Global Oncology Value, Access and Pricing at Daiichi Sankyo. Holding a PharmD degree and two Master’s Degrees, she leads a team of 50 people responsible for setting the global strategic framework for Pricing, Reimbursement, and Access (PRA), Health Economics and Outcome Research (HEOR),…
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this second article, he discusses the problems that occur when using data of poor quality.
